Skip to content

Perspective Therapeutics CATX Net Investment in Lease

Net Investment in Lease at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
Immunome logo
ImmunomeIMNM
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
uniQure logo
uniQureQURE
Precigen logo
PrecigenPGEN

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's net investment in lease?
Perspective Therapeutics (CATX) reported net investment in lease of $2.44M in Q1 2026.
How has Perspective Therapeutics's net investment in lease changed year-over-year?
Perspective Therapeutics's net investment in lease increased by 22.6% year-over-year, from $1.99M to $2.44M.
What is the long-term trend for Perspective Therapeutics's net investment in lease?
Over 5 years (2020 to 2025), Perspective Therapeutics's net investment in lease has grown at a 11.0% compound annual growth rate (CAGR), from $891K to $1.5M.